10-KPeriod: FY2022

Medtronic plc Annual Report, Year Ended Apr 29, 2022

Filed June 23, 2022For Securities:MDT

Summary

Medtronic plc's (MDT) 10-K filing for the fiscal year ended April 28, 2022, showcases a company rebounding from the COVID-19 pandemic, with net sales reaching $31.7 billion, a 5% increase year-over-year. This growth was driven by the recovery of global procedural volumes across its diverse portfolio, which spans Cardiovascular, Medical Surgical, Neuroscience, and Diabetes segments. While overall sales increased, the company navigated challenges including supply chain disruptions, particularly in the latter part of the fiscal year, and the ongoing impact of COVID-19. Medtronic demonstrated solid financial management with free cash flow of $6.0 billion and continued commitment to shareholder returns through share repurchases and dividends. The company's strategic focus remains on innovation and market leadership, with significant investment in research and development to drive new product introductions and expand indications. Medtronic's diversified business model, geographic reach, and commitment to its mission of alleviating pain, restoring health, and extending life position it for continued resilience and growth in the global healthcare technology market.

Financial Highlights

55 data points
Beta

Revenue

$31.69B

68.0% Gross Margin

Net Income

$5.06B

16.0% Net Margin

EPS (Diluted)

$3.73

Total Assets

$90.98B

Cash & Equivalents

$3.71B

Free Cash Flow

$5.98B

Financial Statements
Beta
Revenue$31.69B
Cost of Revenue$10.14B
Gross Profit$21.54B
SG&A Expenses$10.29B
Operating Income$5.75B
Interest Expense$553.00M
Net Income$5.06B
EPS (Basic)$3.75
EPS (Diluted)$3.73
Shares Outstanding (Basic)1.34B
Shares Outstanding (Diluted)1.35B

Key Highlights

  • 1Net sales increased by 5% to $31.7 billion, driven by the recovery of global procedural volumes post-COVID-19.
  • 2The Cardiovascular segment saw a 6% increase in net sales, driven by growth in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic divisions.
  • 3The Medical Surgical segment experienced an 11% increase in Surgical Innovations, though overall segment sales grew by 5% due to declines in Respiratory, Gastrointestinal, & Renal.
  • 4Neuroscience sales grew by 7%, with strong performance in Specialty Therapies, partially offset by market dynamics in China.
  • 5The Diabetes segment saw a 3% decrease in net sales, primarily due to U.S. market performance, despite international growth in the MiniMed 780G system.
  • 6Medtronic generated $6.0 billion in free cash flow, demonstrating strong operational cash generation.
  • 7The company repurchased approximately $2.5 billion of its ordinary shares in fiscal year 2022 and had $3.0 billion remaining under its share repurchase authorization.

Frequently Asked Questions

Medtronic's revenue growth in fiscal year 2022 was primarily driven by the recovery of global medical procedure volumes following the impact of the COVID-19 pandemic in the prior year. Key segments like Cardiovascular and Surgical Innovations within Medical Surgical showed strong performance.

Medtronic faced several challenges, including ongoing global supply chain disruptions, particularly impacting certain product lines in the fourth quarter. The company also noted the continued impact of COVID-19 on procedural volumes and healthcare system staffing shortages, as well as specific market dynamics like lockdowns in China and potential national volume-based pricing tenders in the Neuroscience segment.

Medtronic maintained a strong liquidity position with $3.7 billion in cash and cash equivalents and $6.9 billion in current investments. The company reduced its total debt to $24.1 billion from $26.4 billion. Medtronic also continued to return value to shareholders through share repurchases, utilizing $3.0 billion of its authorized repurchase program during fiscal year 2022.

Medtronic's strategic priorities include leveraging its pipeline to win market share, accelerating innovation-driven growth, creating and disrupting markets with technology, and empowering its operating units to be more nimble and competitive. The company continues to invest in research and development to bring new technologies and therapies to patients.